Adverse Events of Lutetium-177-PSMA-617 Revealed
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
Tag: FDA Adverse Event Reporting System
Immune Checkpoint Inhibitors Linked to Heart Inflammation
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, opening new horizons in the fight against malignancies by unleashing the immune ...
Global Study Finds CAR-T Cell Therapy Associated with Elevated Risk of Secondary Primary Malignancies
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach to treating refractory hematologic malignancies. ...
Safety of Pemetrexed, Platinum ± Pembrolizumab
In the evolving landscape of lung cancer treatment, the integration of immune checkpoint inhibitors (ICIs) with conventional chemotherapy regimens has ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!